Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genmab's commercial stockpile

Since the start of the year, Genmab A/S has been mulling whether to exercise an option under a 2006 deal with GlaxoSmithKline plc to co-promote cancer antibody HuMax-CD20 ofatumumab. Recent developments in two other alliances may have tipped the scales towards pulling the trigger on building the commercial infrastructure.

Until the company's December deal with GlaxoSmithKline (LSE:GSK; GSK, London, U.K.), all of the biotech's deals were done in exchange for royalties but lacked co-promotion rights. The GSK deal includes

Read the full 791 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers